Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome

22 Feb 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Platelet Disorders and Treatments
Share to Retinopathy of Prematurity Studies
Share to Vascular Malformations and Hemangiomas

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 30803705
DOI: 10.1016/j.ajhg.2019.01.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Pharmacodynamic Study of Miransertib in Individuals with Proteus SyndromePMID 30803705Read ↗

Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092).Semantic proximity Read ↗

PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.Semantic proximity Read ↗

Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndromeSemantic proximity Read ↗

European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin geneSemantic proximity Read ↗

Somatic non-cancerous PIK3CA-related overgrowth syndrome treated with alpelisib in North AmericaSemantic proximity Read ↗

The safety and efficacy of metformin in fragile X syndrome: An open-label studySemantic proximity Read ↗

Progranulin as a biomarker and potential therapeutic agentSemantic proximity Read ↗

Baricitinib treatment in children with COPA syndrome.Semantic proximity Read ↗

Alternative bisphosphonate targets and mechanisms of actionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.